Commercial-scale mRNA synthesis for the development and production of vaccines typically involves in vitro transcription (IVT) of a synthetic DNA template comprised of an antigen sequence and several recognition sequences including a capping region, untranslated region (UTRs), and a poly-A tail. The recognition sequences are added to promote the post-transcriptional stability and translatability of the functional mRNA molecule.